NCT04676867View on ClinicalTrials.gov

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
Covid19
Interventions
DRUG

Dalcetrapib

Dalcetrapib 300 mg Film-Coated Tablets

OTHER

Placebo

Placebo Tablets

Trial Locations (1)

H1T 1C8

Institut de Cardiologie de Montréal, Montreal

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

The Montreal Health Innovations Coordinating Center (MHICC)

OTHER

collaborator

Covance

INDUSTRY

lead

DalCor Pharmaceuticals

INDUSTRY

NCT04676867 - Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter